Search | Clinical Trials Finder

Conditions: Neutrophil Chemotactic Response
Interventions: Exercise, ProLab 200mg caffeine capsule, Ethanol ingestion, Glucose Tolerance Drink; Behavioral · Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dehydration
Interventions: Distilled water, Medical Food 1, Medical Food 2, Pedialyte, Gatorade; Other
Lead sponsor: W. Larry Kenney; Other
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions: Levothyroxine, Liothyronine, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Lymphoproliferative Disorder
Interventions: rituximab, cyclophosphamide, methylprednisolone, prednisone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Bone Metabolism
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 70 Years · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 34
States / cities: Greenbrae, California • Los Banos, California • San Diego, California + 31 more

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 108
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more

Conditions: Impaired Glucose Tolerance (IGT), Diabetes
Interventions: Exenatide, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Pioglitazone, Metformin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more

Conditions: Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions: Sitagliptin, glargine, lispro; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 1
Interventions: G-Pen Mini™ (glucagon injection), Glucose Tablets; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more

Conditions: Breast Cancer, Metastatic Cancer
Interventions: capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Type 2 Diabetes
Interventions: Glipizide, Glipizide and Glargine; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Use Disorder
Interventions: Suvorexant 10 mg, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: End Stage Renal Disease
Interventions: nutritional supplement, recombinant human growth hormone (rcGH), exercise; Dietary Supplement · Drug · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 72
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more

Conditions: Glioblastoma (GBM)
Interventions: Ketogenic Diet, Radiation therapy, Temozolomide; Dietary Supplement · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Human Immunodeficiency Virus, Obesity
Interventions: dual-energy X-ray absorptiometry (DEXA) scan, Carotid and branchial artery ultrasound, 2-hour oral glucose tolerace test, Blood collection; Radiation · Other · Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions: Alogliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 5,380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 292
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more

Conditions: Prediabetes
Interventions: Sitting OGTT, Standing OGTT, Sitting CGM, Standing CGM; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

Effects of Amino Acid/Electrolyte-based Beverages on Hydration Status

Energy Metabolism in Thyroidectomized Patients

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

International Care Bundle Evaluation in Cerebral Hemorrhage Research

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Sympathetic Activation in Obesity

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Acute Effect of Exenatide on Brain Glucose Metabolism

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

Chemotherapeutic Agents in Brain/Breast

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Adipose Tissue and Immune Activation in HIV

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Effects of Standing on Glycemia in Prediabetic Adults